{"id":59083,"date":"2026-03-09T13:07:31","date_gmt":"2026-03-09T05:07:31","guid":{"rendered":"https:\/\/flcube.com\/?p=59083"},"modified":"2026-03-09T13:07:32","modified_gmt":"2026-03-09T05:07:32","slug":"cspcs-syh2059-inhalation-powder-wins-fda-ind-approval-pde4b-inhibitor-targets-pulmonary-fibrosis-with-enhanced-delivery","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59083","title":{"rendered":"CSPC&#8217;s SYH2059 Inhalation Powder Wins FDA IND Approval \u2013 PDE4B Inhibitor Targets Pulmonary Fibrosis with Enhanced Delivery"},"content":{"rendered":"\n<p><strong>CSPC Pharmaceutical Group Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1093:HKG\">HKG: 1093<\/a>) announced <strong>FDA clearance<\/strong> to initiate a <strong>clinical study<\/strong> for <strong>SYH2059 inhalation powder<\/strong>, a <strong>selective PDE4B inhibitor<\/strong> for <strong>pulmonary fibrosis (PF)<\/strong> including <strong>idiopathic pulmonary fibrosis (IPF)<\/strong> and <strong>progressive pulmonary fibrosis (PPF)<\/strong>. The <strong>Category 1 chemical drug<\/strong> represents CSPC&#8217;s <strong>second FDA IND<\/strong> for the asset, following <strong>tablet formulation approval in February 2025<\/strong>, demonstrating a <strong>dual-route development strategy<\/strong> to maximize therapeutic potential in the high-unmet-need fibrotic lung disease market.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>U.S. Food and Drug Administration (FDA)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>IND clearance (Phase I-ready)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>SYH2059 inhalation powder<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Selective PDE4B inhibitor (Category 1 chemical drug)<\/td><\/tr><tr><td><strong>Indications<\/strong><\/td><td>Pulmonary fibrosis (PF), idiopathic pulmonary fibrosis (IPF), progressive pulmonary fibrosis (PPF)<\/td><\/tr><tr><td><strong>Developer<\/strong><\/td><td>CSPC Pharmaceutical Group (HKG: 1093)<\/td><\/tr><tr><td><strong>Prior Approval<\/strong><\/td><td>SYH2059 tablet \u2013 FDA IND (Feb\u202f2025)<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>March 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism\">Drug Profile &amp; Mechanism<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>SYH2059 Profile<\/th><\/tr><\/thead><tbody><tr><td><strong>Target<\/strong><\/td><td>Cyclic nucleotide phosphodiesterase 4B (PDE4B)<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>\u2022 Anti-inflammatory: Modulates inflammatory factor release<br>\u2022 Anti-fibrotic: Inhibits fibroblast proliferation and differentiation<\/td><\/tr><tr><td><strong>Formulation Strategy<\/strong><\/td><td>Dual development: Oral tablet (systemic) + Inhalation powder (localized lung delivery)<\/td><\/tr><tr><td><strong>Selectivity<\/strong><\/td><td>Superior PDE4B selectivity vs. pan-PDE4 inhibitors (roflumilast, apremilast)<\/td><\/tr><tr><td><strong>Potency<\/strong><\/td><td>Significantly enhanced target engagement vs. competitors<\/td><\/tr><tr><td><strong>Preclinical Efficacy<\/strong><\/td><td>Markedly superior to existing drugs in disease animal models<\/td><\/tr><tr><td><strong>PK\/PD<\/strong><\/td><td>Favorable pharmacokinetics; good safety profile<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Inhalation Advantage for PF:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Localized delivery:<\/strong> Direct targeting of fibrotic lung tissue vs. systemic exposure<\/li>\n\n\n\n<li><strong>Dose optimization:<\/strong> Higher lung concentrations with reduced systemic side effects<\/li>\n\n\n\n<li><strong>Patient convenience:<\/strong> Dry powder inhaler aligns with respiratory disease management paradigms<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape-amp-market-context\">Competitive Landscape &amp; Market Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Competitor<\/th><th>Product<\/th><th>Mechanism<\/th><th>Status<\/th><th>SYH2059 Differentiation<\/th><\/tr><\/thead><tbody><tr><td><strong>Boehringer Ingelheim<\/strong><\/td><td>Ofev (nintedanib)<\/td><td>Tyrosine kinase inhibitor<\/td><td>Approved (IPF, PPF)<\/td><td>PDE4B selectivity vs. multi-kinase; potentially better tolerability<\/td><\/tr><tr><td><strong>Roche<\/strong><\/td><td>Esbriet (pirfenidone)<\/td><td>Anti-fibrotic (mechanism unclear)<\/td><td>Approved (IPF)<\/td><td>Superior efficacy in preclinical models; dual formulation flexibility<\/td><\/tr><tr><td><strong>AstraZenenca<\/strong><\/td><td>Roflumilast (Daxas)<\/td><td>Pan-PDE4 inhibitor<\/td><td>Approved (COPD)<\/td><td>PDE4B selectivity avoids GI\/weight side effects of pan-PDE4<\/td><\/tr><tr><td><strong>CSPC<\/strong><\/td><td><strong>SYH2059<\/strong><\/td><td><strong>Selective PDE4B inhibitor<\/strong><\/td><td><strong>Phase I-ready (inhalation + oral)<\/strong><\/td><td><strong>First-in-class selectivity; China-led global development<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Market Opportunity:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>IPF\/PPF Market:<\/strong> Global market ~$4 billion; limited therapeutic options with significant side effect burdens<\/li>\n\n\n\n<li><strong>Unmet Need:<\/strong> Nintedanib and pirfenidone slow decline but don&#8217;t reverse fibrosis; patients need better-tolerated alternatives<\/li>\n\n\n\n<li><strong>China Angle:<\/strong> CSPC&#8217;s domestic leadership in respiratory generics supports innovative drug development infrastructure<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-strategy-amp-outlook\">Development Strategy &amp; Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Phase<\/th><th>Formulation<\/th><th>Timeline<\/th><th>Strategic Objective<\/th><\/tr><\/thead><tbody><tr><td><strong>Phase I<\/strong><\/td><td>Inhalation powder<\/td><td>2026<\/td><td>Safety, tolerability, pulmonary deposition<\/td><\/tr><tr><td><strong>Phase I\/II<\/strong><\/td><td>Tablet (ongoing)<\/td><td>2025-2027<\/td><td>Systemic exposure; biomarker validation<\/td><\/tr><tr><td><strong>Phase II<\/strong><\/td><td>Both formulations<\/td><td>2027-2028<\/td><td>Efficacy comparison; formulation selection for Phase III<\/td><\/tr><tr><td><strong>Regulatory Pathway<\/strong><\/td><td>Dual NDA potential<\/td><td>2029-2030<\/td><td>Inhalation for IPF (localized disease); tablet for PPF (systemic component)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, formulation strategy, and competitive positioning for SYH2059. Actual results may differ due to trial outcomes, regulatory requirements, and competitive dynamics in the pulmonary fibrosis market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026030601264_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026030601264_c.\"><\/object><a id=\"wp-block-file--media-ac55c9ab-43fe-47c1-9e66-2ef25d6cd28e\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026030601264_c.pdf\">2026030601264_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026030601264_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-ac55c9ab-43fe-47c1-9e66-2ef25d6cd28e\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CSPC Pharmaceutical Group Ltd (HKG: 1093) announced FDA clearance to initiate a clinical study for&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,171,855],"class_list":["post-59083","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-cspc-pharmaceutical","tag-hkg-1093"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CSPC&#039;s SYH2059 Inhalation Powder Wins FDA IND Approval \u2013 PDE4B Inhibitor Targets Pulmonary Fibrosis with Enhanced Delivery - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"CSPC Pharmaceutical Group Ltd (HKG: 1093) announced FDA clearance to initiate a clinical study for SYH2059 inhalation powder, a selective PDE4B inhibitor for pulmonary fibrosis (PF) including idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). The Category 1 chemical drug represents CSPC&#039;s second FDA IND for the asset, following tablet formulation approval in February 2025, demonstrating a dual-route development strategy to maximize therapeutic potential in the high-unmet-need fibrotic lung disease market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=59083\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CSPC&#039;s SYH2059 Inhalation Powder Wins FDA IND Approval \u2013 PDE4B Inhibitor Targets Pulmonary Fibrosis with Enhanced Delivery\" \/>\n<meta property=\"og:description\" content=\"CSPC Pharmaceutical Group Ltd (HKG: 1093) announced FDA clearance to initiate a clinical study for SYH2059 inhalation powder, a selective PDE4B inhibitor for pulmonary fibrosis (PF) including idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). The Category 1 chemical drug represents CSPC&#039;s second FDA IND for the asset, following tablet formulation approval in February 2025, demonstrating a dual-route development strategy to maximize therapeutic potential in the high-unmet-need fibrotic lung disease market.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=59083\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-09T05:07:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-09T05:07:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59083#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59083\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CSPC&#8217;s SYH2059 Inhalation Powder Wins FDA IND Approval \u2013 PDE4B Inhibitor Targets Pulmonary Fibrosis with Enhanced Delivery\",\"datePublished\":\"2026-03-09T05:07:31+00:00\",\"dateModified\":\"2026-03-09T05:07:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59083\"},\"wordCount\":478,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"CSPC Pharmaceutical\",\"HKG: 1093\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59083#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59083\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=59083\",\"name\":\"CSPC's SYH2059 Inhalation Powder Wins FDA IND Approval \u2013 PDE4B Inhibitor Targets Pulmonary Fibrosis with Enhanced Delivery - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-09T05:07:31+00:00\",\"dateModified\":\"2026-03-09T05:07:32+00:00\",\"description\":\"CSPC Pharmaceutical Group Ltd (HKG: 1093) announced FDA clearance to initiate a clinical study for SYH2059 inhalation powder, a selective PDE4B inhibitor for pulmonary fibrosis (PF) including idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). The Category 1 chemical drug represents CSPC's second FDA IND for the asset, following tablet formulation approval in February 2025, demonstrating a dual-route development strategy to maximize therapeutic potential in the high-unmet-need fibrotic lung disease market.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59083#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59083\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59083#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CSPC&#8217;s SYH2059 Inhalation Powder Wins FDA IND Approval \u2013 PDE4B Inhibitor Targets Pulmonary Fibrosis with Enhanced Delivery\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CSPC's SYH2059 Inhalation Powder Wins FDA IND Approval \u2013 PDE4B Inhibitor Targets Pulmonary Fibrosis with Enhanced Delivery - Insight, China&#039;s Pharmaceutical Industry","description":"CSPC Pharmaceutical Group Ltd (HKG: 1093) announced FDA clearance to initiate a clinical study for SYH2059 inhalation powder, a selective PDE4B inhibitor for pulmonary fibrosis (PF) including idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). The Category 1 chemical drug represents CSPC's second FDA IND for the asset, following tablet formulation approval in February 2025, demonstrating a dual-route development strategy to maximize therapeutic potential in the high-unmet-need fibrotic lung disease market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=59083","og_locale":"en_US","og_type":"article","og_title":"CSPC's SYH2059 Inhalation Powder Wins FDA IND Approval \u2013 PDE4B Inhibitor Targets Pulmonary Fibrosis with Enhanced Delivery","og_description":"CSPC Pharmaceutical Group Ltd (HKG: 1093) announced FDA clearance to initiate a clinical study for SYH2059 inhalation powder, a selective PDE4B inhibitor for pulmonary fibrosis (PF) including idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). The Category 1 chemical drug represents CSPC's second FDA IND for the asset, following tablet formulation approval in February 2025, demonstrating a dual-route development strategy to maximize therapeutic potential in the high-unmet-need fibrotic lung disease market.","og_url":"https:\/\/flcube.com\/?p=59083","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-09T05:07:31+00:00","article_modified_time":"2026-03-09T05:07:32+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=59083#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=59083"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CSPC&#8217;s SYH2059 Inhalation Powder Wins FDA IND Approval \u2013 PDE4B Inhibitor Targets Pulmonary Fibrosis with Enhanced Delivery","datePublished":"2026-03-09T05:07:31+00:00","dateModified":"2026-03-09T05:07:32+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=59083"},"wordCount":478,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","CSPC Pharmaceutical","HKG: 1093"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=59083#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=59083","url":"https:\/\/flcube.com\/?p=59083","name":"CSPC's SYH2059 Inhalation Powder Wins FDA IND Approval \u2013 PDE4B Inhibitor Targets Pulmonary Fibrosis with Enhanced Delivery - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-09T05:07:31+00:00","dateModified":"2026-03-09T05:07:32+00:00","description":"CSPC Pharmaceutical Group Ltd (HKG: 1093) announced FDA clearance to initiate a clinical study for SYH2059 inhalation powder, a selective PDE4B inhibitor for pulmonary fibrosis (PF) including idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). The Category 1 chemical drug represents CSPC's second FDA IND for the asset, following tablet formulation approval in February 2025, demonstrating a dual-route development strategy to maximize therapeutic potential in the high-unmet-need fibrotic lung disease market.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=59083#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=59083"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=59083#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CSPC&#8217;s SYH2059 Inhalation Powder Wins FDA IND Approval \u2013 PDE4B Inhibitor Targets Pulmonary Fibrosis with Enhanced Delivery"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59083","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=59083"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59083\/revisions"}],"predecessor-version":[{"id":59085,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59083\/revisions\/59085"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=59083"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=59083"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=59083"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}